These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8361996)

  • 1. Cyclosporin metabolism in transplant patients.
    Christians U; Sewing KF
    Pharmacol Ther; 1993; 57(2-3):291-345. PubMed ID: 8361996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative cyclosporine metabolic pathways and toxicity.
    Christians U; Sewing KF
    Clin Biochem; 1995 Dec; 28(6):547-59. PubMed ID: 8595701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of rat cytochrome P450 isozymes involved in the covalent binding of cyclosporin A to microsomal proteins.
    Sadrieh N; Thomas PE
    Toxicol Appl Pharmacol; 1994 Aug; 127(2):222-32. PubMed ID: 8048065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The determination of metabolite M17 and its meaning for immunosuppressive cyclosporin therapy.
    Khoschsorur G; Auer T; Lanzer G; Petritsch P; Holzer H; Tscheliessnigg KH
    Angiology; 1998 Apr; 49(4):307-14. PubMed ID: 9555934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.
    Kirchner GI; Winkler M; Mueller L; Vidal C; Jacobsen W; Franzke A; Wagner S; Blick S; Manns MP; Sewing KF
    Br J Clin Pharmacol; 2000 Nov; 50(5):449-54. PubMed ID: 11069439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sites of biotransformation for the cyclosporin derivative SDZ IMM 125 using human liver and kidney slices and intestine. Comparison with rat liver slices and cyclosporin A metabolism.
    Vickers AE; Fisher RL; Brendel K; Guertler J; Dannecker R; Keller B; Fischer V
    Drug Metab Dispos; 1995 Mar; 23(3):327-33. PubMed ID: 7628297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of cyclosporin G (OG37-325), cyclosporin A, and their metabolites on the release of endothelin and prostacyclin from primary renal and aortic endothelial cell lines.
    Langman LJ; Yatscoff RW
    Ther Drug Monit; 1994 Oct; 16(5):450-7. PubMed ID: 7846742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of metabolites and calcineurin inhibition on C2 monitoring in renal transplant patients.
    Karamperis N; Koefoed-Nielsen P; Bagger Sørensen A; Højskov C; Poulsen J; Jørgensen K
    Nephrol Dial Transplant; 2005 Mar; 20(3):618-21. PubMed ID: 15671072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporin clinical pharmacokinetics.
    Fahr A
    Clin Pharmacokinet; 1993 Jun; 24(6):472-95. PubMed ID: 8513650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-pass metabolism of cyclosporin by the gut.
    Kolars JC; Awni WM; Merion RM; Watkins PB
    Lancet; 1991 Dec; 338(8781):1488-90. PubMed ID: 1683920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Critical analysis of the immunosuppressive activity and of the toxicity of cyclosporine metabolites].
    Garraffo R
    Therapie; 1992; 47(4):311-7. PubMed ID: 1494794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholestasis and kidney dysfunction in liver transplant patients reduces cyclosporine metabolite excretion.
    Tötterman A; Lalla M; Salmela K; Höckerstedt K
    Transpl Int; 1992; 5 Suppl 1():S190-2. PubMed ID: 14621772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450.
    Pichard L; Domergue J; Fourtanier G; Koch P; Schran HF; Maurel P
    Biochem Pharmacol; 1996 Mar; 51(5):591-8. PubMed ID: 8615894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells.
    Gan LS; Moseley MA; Khosla B; Augustijns PF; Bradshaw TP; Hendren RW; Thakker DR
    Drug Metab Dispos; 1996 Mar; 24(3):344-9. PubMed ID: 8820426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506.
    Ezeamuzie CI
    Int J Immunopharmacol; 1996 Apr; 18(4):263-70. PubMed ID: 8894806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of hepatic function using the pharmacokinetics of a therapeutically administered drug. Application to the immunosuppressant cyclosporin.
    Weber W; Looby M; Brockmöller J
    Clin Pharmacokinet; 1992 Jul; 23(1):69-83. PubMed ID: 1617860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus.
    Akhlaghi F; Dostalek M; Falck P; Mendonza AE; Amundsen R; Gohh RY; Asberg A
    Ther Drug Monit; 2012 Feb; 34(1):38-45. PubMed ID: 22210099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin metabolism by human gastrointestinal mucosal microsomes.
    Webber IR; Peters WH; Back DJ
    Br J Clin Pharmacol; 1992 Jun; 33(6):661-4. PubMed ID: 1389941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synergistic immunosuppressive potential of cyclosporin metabolite combinations.
    Radeke HH; Christians U; Sewing KF; Resch K
    Int J Immunopharmacol; 1992 May; 14(4):595-604. PubMed ID: 1521927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance.
    Rivory LP; Qin H; Clarke SJ; Eris J; Duggin G; Ray E; Trent RJ; Bishop JF
    Eur J Clin Pharmacol; 2000 Aug; 56(5):395-8. PubMed ID: 11009048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.